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Cyanobacteria (= blue-green algae) are prolific producers of structurally distinct and biologically active metabolites.  In the continuation of 
our search for new sources of anti-infective natural products, we have assessed the in vitro antiprotozoal (Plasmodium falciparum, 
Trypanosoma brucei rhodesiense, T. cruzi, Leishmania donovani) and antitubercular (Mycobacterium tuberculosis) potential of samples of 
two terrestrial cyanobacteria, Nostoc commune (collected when desiccated and wet) and Rivularia biasolettiana. The cytotoxic potential of 
the extracts was also evaluated against primary L6 cells. Except for T. cruzi and M. tuberculosis, the crude extracts were active against all the 
organisms tested and showed no toxicity. The crude extracts were then partitioned between n-hexane, chloroform and aqueous methanol and 
retested against the same panel of pathogens.  The chloroform sub-extracts of both N. commune samples showed significant activity against 
T. b. rhodesiense (IC50 values 2.0 and 3.5 μg/mL) and P. falciparum (IC50s 7.4 and 5.8 μg/mL), with low toxicity. This trend was also true for 
R. biasolettiana extracts, and its chloroform sub-extract showed notable activity against all parasitic protozoa. There were differences in the 
biological activity profiles of extracts derived from desiccated and hydrated forms of N. commune. To our knowledge, this is the first study 
assessing the anti-infective activity of desiccated and hydrated forms of N. commune, as well as R. biasolettiana. Furthermore, the present 
work reports such biological activity in terrestrial cyanobacteria from Ireland for the first time. These results warrant the further study of Irish 
terrestrial cyanobacteria as a valuable source of new natural product leads for the treatment of parasitic protozoal infections. 
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Approximately one-third of the world’s population is 
infected with tuberculosis (TB), the most prevalent 
infectious disease worldwide that kills approximately two 
million people annually [1]. Resistant and/or extremely 
drug-resistant strains of Mycobacterium tuberculosis are 
emerging in both developing and developed countries to 
pose a serious global health problem. Parasitic, mostly 
vector-borne diseases, for example, malaria, leishmaniasis 
and trypanosomiasis, also affect large populations in 
impoverished tropical regions. The most severe form of 
malaria is caused by the protozoan parasite Plasmodium 
falciparum and is transmitted to humans by female 
mosquitoes. Approximately 40% of the earth’s population 
lives in malaria-endangered areas, and each year about      
1 million people, mainly very young children, die of it [2]. 
The WHO estimates that more than 200 million people   
are at risk of either leishmaniasis or trypanosomiasis 
worldwide. Leishmaniasis is widespread across many 
tropical regions, such as India, Sudan, and Brazil. Among 
the three forms of leishmaniasis (cutaneous, mucosal, and 
visceral), the last (VL) represents the greatest threat to 
human health. VL is a sandfly-borne infection caused by 
Leishmania donovani, L. infantum, and L. chagasi. If left 
untreated, it can be 100% fatal within two years [3]. 
African trypanosomiasis (sleeping sickness), which is 
transmitted to humans by tsetse flies, is caused by 
Trypanosoma brucei rhodesiense and T. b. gambiense. It 
affects about half a million people on the African 
continent. Because the parasite is able to pass through the 
blood-brain barrier, the chronic phases of the disease can 
produce severe brain damage and death [4]. American 
trypanosomiasis (Chagas’ disease) is endemic to 21 
countries in S. America. The causative agent of the disease 
is T. cruzi, which is transmitted to humans by triatomine 
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insects. Chronic stage infection, if left untreated, results in 
neurological disorders, intestinal damage and fatal cardio-
myopathy [5]. Current treatment of all these infections is 
limited to a few drugs, with serious drawbacks in efficacy, 
toxicity and cost. More importantly, drug resistance is 
becoming widespread and threatens their utility. These 
facts, combined with the absence of an efficacious vaccine 
and the lack of systemic vector control strategies, provide 
the rationale in several academic settings for the 
development of novel drugs against these diseases. 
 
Cyanobacteria, an ancient photosynthetic group of 
prokaryotic organisms, are prolific producers of a wide 
range of natural products [6a-6d]. This capability has been 
linked with the fact that these organisms face large 
pressure from either grazers or competing organisms 
forcing them to develop chemical defense strategies for 
survival [7]. Nostoc (Nostocales, Nostocaceae) is a diverse 
genus of colonial cyanobacteria, commonly found in both 
aquatic and terrestrial habitats. The genus currently 
includes about 55 species [8]. Nostoc species, in particular 
N. commune, are well known for their capacity to 
withstand long periods of desiccation, cold and UV 
radiation that enable them to survive in most extreme 
environments. In dry seasons, Nostoc species may lie 
dormant for years, but readily recover when rehydrated. 
The dehydrated colonies, which appear as a black and 
brittle powder, swell into green-brown, gelatinous spheres 
in the presence of humidity [9]. The ability of Nostoc 
colonies to tolerate excessive environmental stress, 
including the long-term water deficit, has been attributed 
to the production of a biochemically complex, extracellular 
polysaccharide (glycan) matrix. The principal components 
of this include water-soluble (mycosporine aminoacids) 
and lipid-soluble (scytonemin) UV absorbing pigments, all 
distributed within a high molecular weight extracellular 
glycan unit [10]. 
 
Rivularia (Nostocales, Rivulariaceae) is a genus of about 
70 species of free-living, colony-forming cyanobacteria 
that can be found in both marine and freshwater 
environments [8]. Species of the genus are cosmopolitan, 
often living in fast-flowing streams, seepages, salt 
marshes, and particularly in the intertidal of rocky shores. 
So far, Rivularia species have mainly remained unexplored 
chemically, and there are only few published chemical and 
biological activity studies. 
 
Nostoc species have been used as both food and medicine 
for centuries [11]. Modern studies continue to confirm the 
biomedical potential of Nostoc species and their chemical 
constituents against a number of human diseases. A few 
previous studies compared the chemical composition 
(mainly fatty acids, lipids and carotenoids) of desiccated 
and wet N. commune [9,12]; however, to our knowledge, 
no study has been carried out previously to compare the 
biological activity profile of dehydrated and hydrated      
N. commune samples. The aim of this study was, therefore, 
to evaluate and compare the in vitro antiprotozoal, 
antitubercular and cytotoxic potential of terrestrial N. 
commune collected from Ireland when desiccated (NC-D) 
and when wet (NC-W). In addition, we screened another 
terrestrial cyanobacterium, Rivularia biasolettiana (RB, 
collected wet from Ireland) for the same biological 
activities. The crude extracts of the cyanobacteria were 
active against several protozoan parasites, and were thus 
partitioned between n-hexane, CHCl3 and water, and 
retested against the same panel of microorganisms. Herein, 
we report the biological activity of the crude, as well as 
solvent sub-extracts obtained from three crude extracts. 
 
The crude extracts of the cyanobacteria were tested against 
P. falciparum (erythrocytic stages of drug-resistant K1 
strain), T. brucei rhodesiense (bloodstream forms), T. cruzi 
(intracellular amastigotes in L6 rat skeletal myoblasts), L. 
donovani (axenic amastigotes) and the tubercle bacillus 
(M. tuberculosis strain H37Rv). The toxicity of the 
extracts was also evaluated towards L6 cells, a primary 
cell line derived from mammalian (rat) skeletal myoblasts, 
in order to determine their selectivity. The IC50 and MIC 
values of the extracts and the reference compounds are 
displayed in Table 1.  
 
None of the crude cyanobacterial extracts were active 
against either the tuberculosis bacillus M. tuberculosis or 
T. cruzi at the highest test concentrations. However, all 
three crude extracts had moderate to significant ability to 
inhibit the growth of the remaining protozoan parasites. In 
particular, crude extracts of both desiccated (NC-D-CR) 
and hydrated N. commune (NC-W-CR) had very promising 
activities against T. brucei rhodesiense (IC50 values of 3.5 
and 6.6 μg/mL) and P. falciparum (IC50 values 4.3 and 4.9 μg/mL). The antileishmanial activity of both crude Nostoc 
extracts was only moderate, with the NC-D-CR extract 
being more active (IC50 25.6 and 69.6 μg/mL). The 
potency of the R. biasolettiana crude extract (RB-CR) was 
also modest with IC50 values of 17.7 μg/mL (P. 
falciparum), 27.8 μg/mL (T. b. rhodesiense) and 40.4 
μg/mL (L. donovani). Both N. commune extracts were 
found to lack any cytotoxic potential against L6 cells (IC50 
> 90 μg/mL). The cytotoxic potential of R. bullata crude 
extract was also negligible (IC50 84.3 μg/mL). 
 
These results encouraged us to carry out a coarse 
separation process on the crude extracts. Hence all extracts 
were subjected to a liquid-liquid partition scheme to yield 
n-hexane, chloroform and aqueous methanol sub-extracts. 
All these semi-crude extracts were then subjected to the 
same in vitro screening panel and the results are shown in 
Table 1. No antimycobacterial effect was observed with 
any of the sub-extracts (MIC values > 256 μg/mL). None 
of the aqueous methanol sub-extracts had leishmanicidal 
activity either (IC50 > 100 μg/mL).   
 
Interestingly, the most potent trypanocidal (T. b. 
rhodesiense) and plasmocidal activities were displayed by 
the chloroform sub-extracts of both N. commune samples. 
The same extracts also showed increased potencies, in 
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Table 1: Anti-protozoal, anti-mycobacterial and cytotoxic activities of Irish cyanobacteria. 
 
Sample T. brucei 
rhodesiense 
T.  
cruzi 
L. 
donovani 
P.  
falciparum 
M. tuberculosis 
(MIC) 
Cytotoxicity  
L6 cells 
Control drug 0.005a 0.41 b 0.16 c 0.075d 0.12e 0.009f 
NC-D-Crude  3.5 >90 25.6 4.3 >256 >90 
NC-D-Hexane 80.6 73.2 52.1 28.6 >256 >90 
NC-D-CHCl3 4.0 32.9 16.2 5.8 >256 39.5 
NC-D-Aq.MeOH 31.8 63.8 >100 27.7 >256 >90 
NC-W-Crude  6.6 >90 69.6 4.9 >256 >90 
NC-W-Hexane 54.5 65.0 46.3 17.8 >256 >90 
NC-W-CHCl3 2.0 12.3 16.3 7.4 >256 40.5 
NC-W-Aq.MeOH 74.5 71.1 >100 >50 >256 >90 
RB-Crude  27.8 >90 40.4 17.7 >256 84.3 
RB-Hexane 56.8 54.1 43.1 25.4 >256 >90 
RB-CHCl3 16.1 19.4 16.4 14.8 >256 47.4 
RB-Aq.MeOH >100 85.4 >100 30.7 >256 >90 
All IC50 and MIC values are in μg/mL. IC50 values are mean values from at least 2 replicates of duplicates; MIC values are based on 3 replicates of triplicates (the 
variation is max. 20%). Control drugs: amelarsoprol, bbenznidazole, cmiltefosine, dchloroquine, estreptomycin, fpodophyllotoxin. 
 
comparison with the crude extracts, toward the remaining 
parasites T. cruzi and L. donovani (Table 1). Starting with 
the desiccated N. commune samples, NC-D-CHCl3 sub-
extract showed strong and comparable activities against T. 
b. rhodesiense and P. falciparum, with IC50 values of 4.0 μg/mL and 5.8 μg/mL, respectively. Unlike NC-D-CR, 
NC-D-CHCl3 exhibited some anti-Trypanosoma cruzi 
activity (IC50 32.9 μg/mL), and had almost two-fold higher 
antileishmanial activity (IC50 16.2 μg/mL). The n-hexane-
soluble portion of N. commune collected when dry (NC-D-
Hexane) was active against all four protozoan species with 
IC50 values ranging between 28.6-80.6 μg/mL. As shown 
in Table 1, some modest trypanocidal and antimalarial 
activities were obtained with the aq. MeOH sub-extract 
(NC-D-Aq. MeOH). In general, similar trends and IC50 
values were obtained with the wet (hydrated) N. commune 
(NC-W) sub-extracts. However, against T. b. rhodesiense, 
NC-W-CHCl3 was twice as active (IC50 2.0 μg/mL) than 
the NC-D-CHCl3 sub-extract. In contrast, its 
antiplasmodial activity was slightly weaker (IC50 7.4 μg/mL). Also noteworthy was that the NC-W-Hexane 
extract had slightly lower IC50 values against all four 
parasites (IC50 17.8-65.0 μg/mL), whereas the NC-W-Aq. 
MeOH extract showed only some marginal activity against 
both trypanosomes with IC50 values around 70 μg/mL. A 
similar trend was also observed with R. biasolettiana sub-
extracts. Interestingly, the RB-CHCl3 sub-extract showed 
the best and almost identical IC50 values (14.8-19.4 μg/mL) against all four protozoan parasites. The n-hexane 
sub-extract (RB-Hexane) also retained generally similar 
IC50 values to those of the crude extract towards the 
protozoan parasites (IC50 values 25.4 -56.8 μg/mL), except 
that it had some modest potential against T. cruzi (IC50 
value 54.1 μg/mL). The aq. MeOH extract (RB-Aq. 
MeOH) displayed some plasmocidal effect (IC50 30.7 μg/mL) and very weak anti-T. cruzi activity (IC50 85.4 μg/mL). When tested for toxicity against primary cells, 
only the CHCl3 sub-extracts of the cyanobacterial 
collections exhibited weak potential with IC50 values 
around 40 μg/mL, whereas all other sub-extracts were 
devoid of any cytotoxicity (IC50 > 90 μg/mL). 
 
In recent years, a number of cyanobacteria have been 
studied for their anti-infective potential to yield potent, 
novel natural products [6,13]. The promising biological 
activities and intricate structures of these metabolites have 
also led to several synthetic efforts [14,15].  Encouraged 
by these studies, we decided to screen for biological 
activity two terrestrial cyanobacterial species of Irish 
origin. One major aim of the project was to evaluate, 
comparatively, the biological potencies of both desiccated 
and hydrated forms of N. commune, collected from the 
same site at different times of the year. The results outlined 
here indicate that both forms seem to have similar, but still 
variable biological activities. This may lie in differences in 
their chemical compositions in different seasons of 
collection. Our initial TLC studies (data not shown) point 
out similarities in the crude and semi-crude extracts 
derived from both forms, but they do not appear identical. 
Currently, we are trying to establish more sophisticated 
chemical profiling techniques to compare the chemical 
compositions of these crude and semi-crude extracts. One 
trend shared by these cyanobacteria though was that the 
bioactivity of the crude extracts was concentrated in the 
CHCl3 sub-extracts. This is a common experience in our 
laboratory, which is probably due to enrichment of 
secondary metabolites in this middle polarity phase after 
the removal of primary metabolites into the n-hexane (fats-
lipids) and the aqueous methanol (sugars) sub-extracts. 
 
The medicinal value of Nostoc species was recognized as 
early as 1500 BC, when they were used to treat gout, 
fistula and cancer [11]. Recent studies indicate their 
hypocholesterolemic [16], anti-inflammatory [17], 
antifungal [18] and acetylcholinesterase inhibitory [19] 
effects. Species of Nostoc have been a valuable source of 
biologically-active compounds, such as the cryptophycins 
with potent anticancer activity. These potent tubulin 
inhibitors have served as template compounds for a semi-
synthetic clinical candidate [20]. A number of other 
bioactive peptides, diterpenes and alkaloids have been 
reported from Nostoc species with cytotoxic, 
antimicrobial, antiviral and antiprotozoal activities [6,20]. 
Nostocarboline, a quaternary beta-carbolinium alkaloid 
derived from a Nostoc sp. and its synthetic derivatives 
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show potent antiprotozoal and antimycobacterial activities 
[14,15]. The hydrated forms of Nostoc species, particularly 
N. commune are consumed as foodstuff, primarily in Asia 
and the Andes [21a,b]. It is a rich source of protein, fat, 
carbohydrate, crude fiber and vitamins [22a,b]. However a 
recent study showed the presence of beta-methylamino-L-
alanine (BMAA), a neurotoxic aminoacid in Nostoc 
species [21a]. It would be of interest to test whether our 
Irish N. commune samples contain BMAA. 
 
A literature survey indicates that Rivularias species have 
been poorly investigated. Several bromoindole alkaloids 
have been isolated from R. firma [23a,b], and some 
Rivularia species have been studied for their fatty acid 
[24a,b] and sugar constituents [25]. Antibacterial, 
antifungal [24b,26] and algicidal [27] effects of some 
species have also been assessed. To our knowledge, this is 
the first study evaluating antiprotozoal, antitubercular and 
cytotoxic potential of a Rivularia species.  
 
The present investigation indicated the in vitro 
antiprotozoal potential of terrestrial cyanobacteria 
collected in the wild from Ireland. In particular, the 
chloroform-soluble portion of these extracts displayed 
highly interesting antiprotozoal activity. Because of the 
promising IC50 values and low toxicity, these extracts of 
cyanobacteria, particularly the chloroform sub-extracts, 
merit further investigation for the isolation and 
characterization of their active metabolites. This is the 
subject of our current research. Antimalarial and 
antiprotozoal activities of some alkaloids obtained from 
Nostoc species have been reported [14,15], but this is the 
first study comparing the antiprotozoal activity of N.  
commune collected in desiccated and hydrated forms. It 
also appears that the current work represents the first 
antiprotozoal, antitubercular and cytotoxic assessment of 
any Rivularia species. To our knowledge, this is also the 
first study assessing such biological activity of Irish 
cyanobacteria. 
 
Experimental 
 
Cyanobacterial samples: All cyanobacterial samples were 
collected in the Burren near Finavarra, Co. Clare, Ireland. 
The dry form of Nostoc commune Vaucher ex Bornet & 
Flahault was collected in May 2007, whereas Rivularia 
biasolettiana Meneghini ex Bornet and the wet form of N. 
commune were collected in November and December 
2007, respectively. Identifications were made by one of us 
(M.G.) based on Whitton [28]. Voucher samples of N. 
commune are lodged in the Herbarium of the Hampshire 
County Council Museums Service in Winchester, 
Hampshire (accession number Bi 2000. 16. 375), and of 
both N. commune and R. biasolettiana at the University of 
London, School of Pharmacy (voucher # GB07-C1 
through GB07-C3).  
 
Extraction and partition: The collected cyanobacteria 
were immediately placed in i-PrOH and stored at -20˚C in 
a freezer until work-up. Algal material was homogenized 
in a household blender and filtered. The residue was 
extracted overnight with CHCl3: MeOH mixtures (3:1 and 
1:1) under continuous stirring at room temperature and 
combined with the initial i-PrOH extract obtained above. 
The combined crude extract was dissolved in 10 mL 
EtOAc: MeOH (1:1) and centrifuged to remove insoluble 
materials. The supernatant was removed, evaporated to 
dryness in vacuo at 30˚C, and used for the initial biological 
assays. A portion of each crude extract (1 g) was dissolved 
in 10% water in MeOH (100 mL) and partitioned against 
n-hexane (3x100 mL). The water content of the MeOH 
phase was then adjusted to 30% by adding water before 
partitioning against CHCl3 (3x100 mL). The n-hexane and 
CHCl3 extracts were evaporated to dryness in vacuo at 
30˚C, whereas the aq. MeOH sub-extract was freeze-dried 
before using in the biological assays. 
 
Trypanocidal activity against T. brucei rhodesiense and 
cytotoxicity: Minimum Essential Medium (50 μL) 
supplemented with 25 mM HEPES, 1g/L additional 
glucose, 1% MEM non-essential amino acids (100 x),    
0.2 mM 2-mercaptoethanol, 1mM Na-pyruvate and 15% 
heat inactivated horse serum was added to each well of a 
96-well microtiter plate [29]. Serial drug dilutions of seven 
3-fold dilution steps (90 - 0.123 μg/mL) were prepared. 
Then 104 bloodstream forms of T. b. rhodesiense STIB 900 
in 50 μL was added to each well and the plate incubated at 
37°C under a 5% CO2 atmosphere for 72 h. Ten μL 
Alamar Blue was then added to each well and incubation 
continued for a further 2-4 h. The plates were read with a 
Spectramax Gemini XS microplate fluorometer using an 
excitation wavelength of 536 nm and an emission 
wavelength of 588 nm. Data were analyzed using the 
microplate reader software Softmax Pro (Molecular 
Devices Cooperation, Sunnyvale, CA, USA). Cytotoxicity 
was assessed using the same assay on rat skeletal 
myoblasts (L6 cells). Melarsoprol and podophyllotoxin 
were the control drugs. 
 
Trypanocidal activity against T. cruzi: Rat skeletal 
myoblasts (L6 cells) were seeded in 96-well microtiter 
plates at 2000 cells/well in 100 μL RPMI 1640 medium 
with 10% FBS and 2 mM l-glutamine. After 24 h, the 
medium was removed and replaced by 100 μL per well 
containing 5000 trypomastigote forms of T. cruzi Tulahuen 
strain C2C4 containing the β-galactosidase (Lac Z) gene 
[30]. After 48 h, the medium was removed from the wells 
and replaced by 100 μL fresh medium with or without a 
serial drug dilution of seven 3-fold dilution steps. After 96 
h of incubation the plates were inspected under an inverted 
microscope to assure growth of the controls and sterility. 
The substrate CPRG/Nonidet (50 μL) was added to all 
wells. A color reaction developed within 2-6 h, which was 
read photometrically at 540 nm. Data were transferred into 
the graphic program Softmax Pro, which calculated IC50 
values. Benznidazole was the standard drug used. 
 
Leishmanicidal activity against L. donovani: Amastigotes 
of L. donovani strain MHOM/ET/67/L82 were grown in 
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axenic culture at 37°C in SM medium at pH 5.4 
supplemented with 10% heat-inactivated fetal bovine serum 
under an atmosphere of 5% CO2 in air. Culture medium 
(100 mL) with 105 amastigotes from axenic culture with or 
without a serial drug dilution were seeded in 96-well 
microtiter plates. Serial drug dilutions were prepared, and 
after 72 h of incubation the plates were inspected under an 
inverted microscope to assure growth of the controls and 
sterile conditions. Ten μL of Alamar Blue was then added to 
each well and the plates incubated for another 2 h [31]. 
Then the plates were read with a Spectramax Gemini XS 
microplate fluorometer using an excitation wavelength of 
536 nm and an emission wavelength of 588 nm. Data were 
analyzed using the software Softmax Pro. Decrease of 
fluorescence (= inhibition) was expressed as percentage of 
the fluorescence of control cultures and plotted against the 
drug concentrations. From the sigmoidal inhibition curves 
the IC50 values were calculated. Miltefosine was used as a 
reference drug. 
 
Antimalarial activity against P. falciparum: In vitro 
activity against erythrocytic stages of P. falciparum was 
determined by a modified [3H]-hypoxanthine incorporation 
assay using drug-resistant K1 strain and the standard drug 
chloroquine. Briefly, parasite cultures incubated in RPMI 
1640 medium with 5% Albumax (without hypoxanthine) 
were exposed to serial drug dilutions in microtiter plates. 
After 48 h of incubation at 37oC in a reduced oxygen 
atmosphere, 0.5 μCi 3H-hypoxanthine was added to each 
well. Cultures were incubated for a further 24 h before they 
were harvested onto glass-fiber filters and washed with 
distilled water. Radioactivity was measured using a 
BetaplateTM liquid scintillation counter (Wallac, Zurich). 
The results were recorded as counts per min (CPM) per well 
at each drug concentration and expressed as a percentage of 
the untreated controls. IC50 values were calculated from 
graphically plotted dose-response curves. 
 
Antitubercular activity against M. tuberculosis: Minimum 
inhibitory concentrations (MICs) were measured using an 
MTT assay based on the method detailed by Montoro et al. 
[32]. Briefly, Middlebrook 7H9 medium (100 μL), 
supplemented with 10% oleic acid-albumin-dextrose-
catalase supplement, 0.5% glycerol and 0.005% tween 80 
was added to each well of a 96-well flat-bottom plate. Serial 
drug dilutions were added to the wells (final concentrations 
of 1-256 μg/mL) and approximately 2.5 x 107 M. 
tuberculosis strain H37Rv in 100 μL was added to each 
well. The plate lid was then sealed with parafilm and the 
plate incubated with gentle rocking (30 oscillations per min) 
for 7 days at 37oC. Ten μL MTT (filter-sterilized at 5 
mg/mL in dH2O) was added to each well and the plates were 
then incubated for a further 24 h. MICs were recorded as the 
lowest concentration at which a purple precipitate of 
formazin did not appear in the wells. Streptomycin was used 
as a positive control. 
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